Joel Gelernter, MD
Biography
Research & Publications
News
Appointments
Biography
Joel Gelernter, MD, is Foundations Fund Professor of Psychiatry and Professor of Genetics and Neurobiology; and Director, Division of Human Genetics (Psychiatry), at the Yale University School of Medicine.
The research focus of his laboratory is genetics of psychiatric illness – phenotypes including cocaine, opioid, nicotine, cannabis, and alcohol dependence, posttraumatic stress disorder (PTSD), depression, and panic and other anxiety disorders. He also studies a range of related phenotypes, including pharmacogenomics; and basic issues in population and complex trait genetics. The overall approach involves study of genetic polymorphism and sequence variation, on a molecular level and from the perspective of population genetics. Dr Gelernter’s laboratory published genomewide association studies (GWAS) for cocaine, cannabis, and opioid dependence, PTSD, alcohol dependence, nicotine dependence, and several related traits. All of these studies have resulted in the identification of novel risk loci.
Education & Training
- FellowshipPsychiatric genetics, NIMH (1988)
- MDSUNY Downstate Medical Center (1983)
- BSYale University, Music & Biology (1979)
Departments & Organizations
- Center for Biomedical Data Science
- Center for the Translational Neuroscience of Alcohol
- Computational Biology and Bioinformatics Track
- Division of Human Genetics
- Division of Molecular Psychiatry
- Gelernter Lab
- Genetics
- Global Health Studies
- Molecular Cell Biology, Genetics and Development
- Neurocognition, Neurocomputation, and Neurogenetics, Division of
- Neuroscience Research Training Program (NRTP)
- Office of Global Health Education
- Psychiatry
- Psychotherapy Development Center
- Stress & Addiction Clinical Research Program
- VA Alcohol Research Center
- VA-Yale Clinical Neurosciences PTSD Research Program
- Yale Center for Genomic Health
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Global Mental Health Program
- Yale Ventures